Exelixis
EXEL
#1571
Rank
โ‚น941.05 B
Marketcap
โ‚น3,362
Share price
-0.36%
Change (1 day)
79.98%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of December 2024 : โ‚น16.64 Billion

According to Exelixis's latest financial reports the company's total debt is โ‚น16.64 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚น15.81 B0.48%
2022-12-31โ‚น15.73 B312.36%
2021-12-31โ‚น3.81 B6.31%
2020-12-31โ‚น3.58 B4.85%
2019-12-31โ‚น3.42 B228.27%
2018-12-31โ‚น1.04 B9.35%
2017-12-31โ‚น0.95 B-92.58%
2016-12-31โ‚น12.85 B-53.73%
2015-12-31โ‚น27.77 B22.76%
2014-12-31โ‚น22.62 B5.46%
2013-12-31โ‚น21.45 B16.7%
2012-12-31โ‚น18.38 B91.44%
2011-12-31โ‚น9.60 B2.8%
2010-12-31โ‚น9.34 B152.85%
2009-12-31โ‚น3.69 B-34.69%
2008-12-31โ‚น5.65 B18.61%
2007-12-31โ‚น4.76 B-11.49%
2006-12-31โ‚น5.38 B-19.56%
2005-12-31โ‚น6.69 B4.96%
2004-12-31โ‚น6.38 B26.18%
2003-12-31โ‚น5.05 B42.65%
2002-12-31โ‚น3.54 B50.13%
2001-12-31โ‚น2.36 B238.46%
2000-12-31โ‚น0.69 B20.68%
1999-12-31โ‚น0.57 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
โ‚น1.874 T 11,162.90%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น1.625 T 9,664.70%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น3.325 T 19,882.39%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น4.465 T 26,731.15%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.241 T 31,394.63%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3.195 T 19,097.90%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.810 T 34,810.36%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น0.28 B-98.29%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3.37 B-79.73%๐Ÿ‡บ๐Ÿ‡ธ USA